In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.

Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D) / E. Dozio, V. Corradi, M. Proglio, E. Vianello, L. Menicanti, R. Rigolini, C. Caprara, M. de Cal, M.M. Corsi Romanelli, C. Ronco. - In: DIABETES RESEARCH AND CLINICAL PRACTICE. - ISSN 0168-8227. - 140(2018 Jun), pp. 9-17.

Usefulness of glycated albumin as a biomarker for glucose control and prognostic factor in chronic kidney disease patients on dialysis (CKD-G5D)

E. Dozio
;
E. Vianello;M.M. Corsi Romanelli;
2018-06

Abstract

In chronic kidney disease patients on dialysis (CKD-G5D) accurate assessment of glycemic control is vital to improve their outcome and survival. The best glycemic marker for glucose control in these patients is still debated because several clinical and pharmacological factors may affect the ability of the available biomarkers to reflect the patient's glycemic status properly. This review discusses the role of glycated albumin (GA) both as a biomarker for glucose control and as a prognostic factor in CKD-G5D; it also looks at the pros and cons of GA in comparison to the other markers and its usefulness in hemodialysis and peritoneal dialysis.
Cardiovascular risk; Diabetes; Dialysis; Glycated albumin; Glycation; Hemodialysis; Mortality; Peritoneal dialysis
Settore MED/05 - Patologia Clinica
26-mar-2018
Article (author)
File in questo prodotto:
File Dimensione Formato  
Dozio et al..pdf

accesso aperto

Tipologia: Pre-print (manoscritto inviato all'editore)
Dimensione 826.39 kB
Formato Adobe PDF
826.39 kB Adobe PDF Visualizza/Apri
1-s2.0-S0168822718303656-main.pdf

accesso riservato

Tipologia: Publisher's version/PDF
Dimensione 977.99 kB
Formato Adobe PDF
977.99 kB Adobe PDF   Visualizza/Apri   Richiedi una copia
Pubblicazioni consigliate

Caricamento pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: http://hdl.handle.net/2434/569784
Citazioni
  • ???jsp.display-item.citation.pmc??? 4
  • Scopus 10
  • ???jsp.display-item.citation.isi??? 8
social impact